Evidence map›Paper›PMID 37783817›Full record

ReviewNature aging2023

Combinatorial interventions in aging.

Andrey A Parkhitko, Elizabeth Filine, Marc Tatar

Abstract readReview
In one paragraph

Review in Nature aging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Methionine restriction and mimetics to ameliorate human aging and disease.Trends in endocrinology and metabolism: TEM · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Improving our understanding of the biology of aging: findings from the Age-It Research Program.The journals of gerontology. Series B, Psychological sciences and social sciences · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Andrey A ParkhitkoAging Institute of UPMC and the University of Pittsburgh, Pittsburgh, PA, USA. aparkhitko@pitt.edu.ORCID http://orcid.org/0000-0001-9852-8329
Elizabeth FilineDepartment of Genetics, Blavatnik Institute, Harvard Medical School, Boston, MA, USA.
Marc TatarDepartment of Ecology, Evolution and Organismal Biology, Brown University, Providence, RI, USA. marc_tatar@brown.edu.ORCID http://orcid.org/0000-0003-3232-6884

Funding

VARIABILITY, STABILITY & SMOOTHNESS OF WALKINGP30AG024827 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JENNIFER S BRACH · 2004 to 2026
$28.6M
Deciphering the crosstalk between methionine metabolism and methyltransferases in health and diseaseR35GM146869 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Andrey A Parkhitko · 2022 to 2026
$2.3M
Genome wide association analysis with Drosophila to discover how metformin effects longevityR01AG069639 · NIA · BROWN UNIVERSITY · PI TATAR, MARC · 2020 to 2024
$2.0M
Aging regulation by non-autonomous signaling from Drosophila gut enteroendocrine cellsR01AG059563 · NIA · BROWN UNIVERSITY · PI TATAR, MARC · 2018 to 2022
$1.9M
Methionine Cycle as a Mechanistic Hub for the Hallmarks of AgingR01AG082801 · NIA · BROWN UNIVERSITY · PI Andrey A Parkhitko, MARC TATAR · 2023 to 2026
$1.7M
Studying methionine flux and its role in aging and neurodegenerationR00AG057792 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PARKHITKO, ANDREY A · 2020 to 2022
$871k
Tyrosine degradation pathway in mitochondrial dysfunction and agingR03AG075651 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PARKHITKO, ANDREY A · 2022 to 2023
$159k
NIA NIH HHS P30 AG024827NIA NIH HHS R00 AG057792NIA NIH HHS R00 AG057792 (P.A.)NIA NIH HHS R01 AG059563NIA NIH HHS R01 AG059563 (T.M.)NIA NIH HHS R01 AG069639NIA NIH HHS R01 AG069639 (T.M.)NIA NIH HHS R01 AG082801NIA NIH HHS R03 AG075651NIA NIH HHS R03 AG075651 (P.A.)NIGMS NIH HHS R35 GM146869NIGMS NIH HHS R35 GM146869 (P.A.)
6 · The paper itself

Abstract

Insight on the underlying mechanisms of aging will advance our ability to extend healthspan, treat age-related pathology and improve quality of life. Multiple genetic and pharmacological manipulations extend longevity in different species, yet monotherapy may be relatively inefficient, and we have limited data on the effect of combined interventions. Here we summarize interactions between age-related pathways and discuss strategies to simultaneously retard these in different organisms. In some cases, combined manipulations additively increase their impact on common hallmarks of aging and lifespan, suggesting they quantitatively participate within the same pathway. In other cases, interactions affect different hallmarks, suggesting their joint manipulation may independently maximize their effects on lifespan and healthy aging. While most interaction studies have been conducted with invertebrates and show varying levels of translatability, the conservation of pro-longevity pathways offers an opportunity to identify 'druggable' targets relevant to multiple human age-associated pathologies.

Indexed as

Healthy AgingQuality of LifeAgingHumansLongevity

Identifiers

PMID37783817
PMCPMC11194689

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.